Akeso’s PCSK9 MONOCLONAL ANTIBODY (EBRONUCIMAB) EARLY COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA

Akeso's Pcsk9 Monoclonal Antibody (ebronucimab) Early Completion Of Patient Enrollment In A Phase Iii Clinical Trial For Primary Hypercholesterolemia And Mixed Hyperlipidemia

Facebook Comments

Leave a Reply

CommentLuv badge